The Effects of Telepractice- Based LSVT-BIG Training in Patients with Parkinson’s Disease in Covid-19 pandemic: Preliminary Results
Objective: To investigate the effects of telepractice-based LSVT-BIG training on balance and mobility parameters in patients with Parkinson’s Disease (PD). Background: Patients with PD who…Parkinson Progression Marker Initiative – New Science/New Cohorts
Objective: The Parkinson Progression Marker Initiative (PPMI) is expanding its cohorts and exploring additional biomarkers of PD progression to test hypotheses of the underlying molecular…IMPACT OF STANDARD-OF-CARE MEDICATIONS ON TIME-OFF READOUTS IN CLINICAL TRIALS. A QUANTITATIVE SYSTEMS PHARMACOLOGY APPROACH
Objective: To mitigate clinical variability of Time-Off with various therapeutic combinations Background: There is increasing interest to use wearable-based digital health measures to continuously monitor…Unilateral Subthalamic Versus Unilateral Pallidal Stimulation in Parkinson’s Disease: A Randomized Double-Blind Crossover Study
Objective: To compare the acute effects of deep brain stimulation (DBS) of unilateral subthalamic nucleus (STN) and unilateral globus pallidus interna (GPi) on motor function…The early post-transplant period in Parkinson’s disease: the low intravenous dose effect.
Objective: To compare the early results of the introduction of MSCs via different routs of administration on the dynamics of the motor symptoms in patients…Global access to Parkinson’s disease treatment
Objective: To examine the availability of PD treatment by country, and analyse differences by national income as defined by the World Bank (high income countries…α-synuclein expression is not mediated by β2-adrenoreceptor modulation in human dopaminergic cells
Objective: Modulation of the β2-adrenoreceptor (also called the β2-adrenergic receptor or β2-adrenoceptor) has been reported to regulate SNCA expression. We sought to determine the expression…Analysis of Amantadine formulations for OFF and Dyskinesia in Parkinson Disease
Objective: Evaluate the effects of amantadine formulations on the treatment of OFF and dyskinesia in Parkinson’s patients. Background: There are currently three formulations of amantadine…Real-world characteristics of advanced Parkinson’s disease patients initiating carbidopa/levodopa enteral suspension
Objective: To describe the real-world characteristics of advanced Parkinson’s disease (APD) patients initiating carbidopa/levodopa enteral suspension (CLES) therapy in USA Background: CLES is an FDA…Electroconvulsive therapy for refractory psychiatric symptoms in GBA-related Parkinson disease patient
Objective: This case report aims to highlight the ECT as a promising option on refractory neuropsychiatric manifestations of PD. Background: In GBA-related PD, non-motor symptoms…
- « Previous Page
- 1
- …
- 100
- 101
- 102
- 103
- 104
- …
- 132
- Next Page »